Global Immunoprotein Diagnostic Testing Market – Industry Trends and Forecast to 2030

Immunoprotein Diagnostic Testing Market Analysis and Size

The huge prevalence of chronic diseases is increasing the demand for immunoprotein diagnostic testing. As per the records of WHO, the Global Health Observatory data recommends that about 1.6 million which results to 2.8% of the total deaths are caused by diabetes. Chemiluminescence assays were rapidly developed with respect to the huge technological advances in immunoprotein diagnostics. There are several technology that are helping in the quick detection of chronic diseases having fully automated tools.

Data Bridge Market Research analyses that the immunoprotein diagnostic testing market is expected to reach USD 14.58 billion by 2030, which is USD 8.36 billion in 2022, and is expected to undergo a CAGR of 7.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Immunoprotein Diagnostic Testing Market Scope and Segmentation

Market Definition

Immunoproteins are the blood proteins which are involved in playing a major role in the functioning of the immune system. These proteins contain an immunological activity against pathogenic substances since they display an abnormal increase in blood concentration thus acting as a standard indicator in disease diagnosis during an unhealthy state. The immunoproteins form a whole body system in cells, tissues or organs which help to balance the dangerous effects of antigens.

Immunoprotein Diagnostic Testing Market Dynamics

Drivers

• Increasing Incidence of Chronic Diseases

The major reason for the growth in the demand for immunoprotein diagnostic testing services is the rise in incidence and incidence rate of chronic diseases. As per the records of WHO, the Global Health Observatory recommends that nearly 1.6 million, which is around 2.8% of the total deaths, are caused by diabetes. Furthermore, lung cancer alone was primarily responsible in 2012 to cause around 1.6 million deaths as per the statistics of WHO report. In this regard, early diagnosis and testing is necessary. This boosts the market growth.

• Rising Incidence of Non-communicable Diseases and Diabetes

As per the WHO records, the number of people having diabetes has increased from 108 million in 1980 to 422 million in 2014, indicating a huge rise in the incidence of diabetes. Furthermore, as per the Global Health Observatory data by WHO in 2017, about 70% of global deaths lead to 39.5 million are caused because of non- communicable diseases (NCD) such as cardiovascular diseases, cancers, chronic lung diseases, and diabetes. Thus, it leads to the increase in these testing patterns.

Opportunities

• Rise in Diagnostic Tests

There are several diagnostic tests that are helping in the expansion of the market growth. C-Reactive Protein (CRP) tests is widely used due to the wide product portfolio of major market players. These tests help to identify inflammation by determining the amount of CRP in the patient. It also help in observing the effectiveness of treatment for several infectious diseases and cancer. Furthermore, free light chain diagnostic tests are expected to show major growth during the forecast period. This is because of their ability to help in detection, diagnosis, and monitoring of plasma cell disorders. This testing is beneficial for patients suffering from light chain-only multiple myeloma, oligosecretory myeloma, or nonsecretory myeloma. Thus, all these tests are increasing the market growth.

• Growing Demand of Chemiluminescence assay

Chemiluminescence assay is projected to show the maximum growth during the forecast period because of its high specificity and sensitivity along with ability to identify antigens in human serum and plasma samples. Chemiluminescence assay is often characterized as a major tool for quick diagnosis of numerous diseases and is determined to be more accurate than fluorescence-based detection of labelled probes. Thus, this assay is certainly growing the market growth.

Restraints/Challenges

• High cost of Diagnostic Tests

Different tests are available for testing chronic diseases, cardiovascular and other conditions such as diabetes. But these tests are of much high cost which is not afforded by many patients, especially belonging to the lower economic groups. Thus, it hampers the market growth.

This immunoprotein diagnostic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoprotein diagnostic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Bio-Rad partnered with Seegene, which is a major market player in multiplex molecular diagnostics, used for the clinical commercialization and huge development of infectious disease diagnostic solutions
• In 2021, Roche collaborated with PathAI, which is a world leader in pathology-based AI-powered technology. The companies collaborated intending to jointly develop an embedded image analysis workflow for different pathologists

Global Immunoprotein Diagnostic Testing Market Scope

The immunoprotein diagnostic testing market is segmented on the basis of type, applications, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• C-Reactive Protein Diagnostic Test
• Complement System Protein Diagnostic Test
• Pre-Albumin Diagnostic Test
• Haptoglobin Diagnostic Test
• Immunoglobulin Diagnostic Test
• Free Light Chain Diagnostic Test
• Others

Applications

• Autoimmune Testing
• Infectious Disease Testing
• Allergy Testing
• Endocrine Testing
• Oncology Testing
• Toxicology Testing
• Others

Technology

• Radioimmunoassay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis
• Enzyme-Linked Immunosorbent Assay
• Others

End-User

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Immunoprotein Diagnostic Testing Regional Analysis/Insights

The immunoprotein diagnostic testing market is analyzed and market size insights and trends are provided by type, applications, technology and end-user as referenced above.

The countries covered in the immunoprotein diagnostic testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the immunoprotein diagnostic testing market because of the growing incidences of cancer with increasing number of diagnostic instruments and laboratories. Furthermore, high occurrence of cancer among the U.S. population also led to the huge growth of this market. Furthermore, high occurrence of cancer among the U.S. population also led to the growth of this market.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to high frequency of cancer and diabetes among the U.S.  population. Surge in number of government initiatives undertaken in Germany to conduct different tests for people who are suffering from multifactorial and chronic diseases, particularly to detect cancer, lung, diabetes, and cardiovascular disease, is one of the major factors which is responsible for the growth in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The immunoprotein diagnostic testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for immunoprotein diagnostic testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the immunoprotein diagnostic testing market. The data is available for historic period 2011-2020.

Competitive Landscape and Global Immunoprotein Diagnostic Testing Market Share Analysis

The immunoprotein diagnostic testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunoprotein diagnostic testing market.

Some of the major players operating in the immunoprotein diagnostic testing market are:

• Abbott (U.S.)
• Abcam plc (U.K.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher. (U.S.)
• DiaSorin S.p.A (Italy)
• Enzo Biochem (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• bioMérieux SA (France)
• Agilent Technologies Inc. (U.S.)
• Enzo Life Sciences, Inc (India)
• Randox Laboratories Ltd (U.K.)
• SERVA Electrophoresis GmbH (Germany)
• Calbiotech (U.S.)
• Eurobio scientific (France)
• Meridian Bioscience, Inc. (U.S.)
• A. Menarini Diagnostics s.r.l (Italy)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Siemens Healthcare GmbH (Germany)

SKU-56900